Minerva Neurosciences, Inc. (NERV)

US — Healthcare Sector
Peers: LGVN  ASBP  NXTC  EDSA  LEXX  SNSE  ANL  FBLG  LPCN  PTHS 

Automate Your Wheel Strategy on NERV

With Tiblio's Option Bot, you can configure your own wheel strategy including NERV - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol NERV
  • Rev/Share 0.0056
  • Book/Share -4.2422
  • PB -1.2682
  • Debt/Equity -1.8686
  • CurrentRatio 6.148
  • ROIC -0.5796

 

  • MktCap 37624524.0
  • FreeCF/Share -2708141.9422
  • PFCF -0.0
  • PE 3.6263
  • Debt/Assets 1.9724
  • DivYield 0
  • ROE -0.0

 

  • Rating B-
  • Score 2
  • Recommendation Sell
  • P/E Score 3
  • DCF Score 3
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation for US Commercial Launch, if Approved
NERV
Published: October 21, 2025 by: GlobeNewsWire
Sentiment: Neutral

Minerva secures $80 million up front and up to an additional $80 million subject to the full exercise of Tranche A warrants. Minerva and the FDA have defined a path forward for roluperidone's clinical development and NDA resubmission.

Read More
image for news Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation for US Commercial Launch, if Approved
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Business Updates
NERV
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral

BURLINGTON, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the fourth quarter and year ended December 31, 2024.

Read More
image for news Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Business Updates

About Minerva Neurosciences, Inc. (NERV)

  • IPO Date 2014-07-01
  • Website https://www.minervaneurosciences.com
  • Industry Biotechnology
  • CEO Remy Luthringer
  • Employees 8
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.